Last reviewed 2026-04-23 · How we verify

ARQ-151 cream 0.05%

ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses.

ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses. Used for Atopic dermatitis.

At a glance

Mechanism of action

By selectively inhibiting JAK1, ARQ-151 reduces the activation of downstream signaling pathways such as STAT, which are involved in the production of pro-inflammatory cytokines and chemokines, thereby alleviating inflammation and associated symptoms.

Approved indications

• Atopic dermatitis

Common side effects

• Application site irritation
• Headache

Key clinical trials

• Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (PHASE3)
• Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) (PHASE3)
• Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis (PHASE2)
• Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema (PHASE1)
• Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ARQ-151 cream 0.05% CI brief — competitive landscape report
• ARQ-151 cream 0.05% updates RSS · CI watch RSS
• Arcutis Biotherapeutics, Inc. portfolio CI